University of Cincinnati and Johns Hopkins Develop Nanofibre-Based Therapy for Glioblastoma
Researchers from the University of Cincinnati and Johns Hopkins Medicine have developed a promising nanofibre-based drug delivery system designed to improve treatment outcomes for glioblastoma, the most aggressive form of brain cancer in adults.
The innovative platform uses electrospun nanofibres embedded with a combination of three approved drugs—temozolomide, acriflavine and PT2385.
The system delivers both immediate and sustained doses of medicine directly to the tumour site, helping to overcome challenges associated with conventional therapies.
Published in ACS Biomaterials Science & Engineering, the study demonstrated that the three-drug combination produced strong synergistic effects across multiple glioblastoma models and significantly improved survival in animal studies.
In preclinical testing, treated mice survived more than twice as long as untreated animals, with 40% remaining alive beyond the 120-day study period.
The NanoMesh technology was developed to address key treatment barriers, including tumour recurrence, drug resistance and the blood-brain barrier.
Researchers believe the platform could offer a more effective localised treatment approach while reducing systemic side effects.
The study was supported by the National Institutes of Health, and further research is underway to advance the technology towards clinical application.
